ACIP Vaccine Recommendations

Advisory Committee on Immunization Practices (ACIP) from CDC

The Advisory Committee on Immunization Practices (ACIP) develops recommendations on how to use vaccines and passive immunizations to control diseases in the United States. Learn more about ACIP.
Results (192)
  • COVID-19
Current
Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR December 12, 2024 / 73(49);1118–1123
  • Meningococcal B
Current
New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, October 2024
MMWR December 12, 2024 / 73(49);1118–1123
  • Hepatitis B
Current
Updated Recommendation for Universal Hepatitis B Vaccination in Adults Aged 19–59 Years — United States, 2024
MMWR Weekly / December 5, 2024 / 73(48);1106
  • Hib (Haemophilus Influenzae Type B)
Current
Use of Haemophilus influenzae Type b–Containing Vaccines Among American Indian and Alaska Native Infants: Updated Recommendations of the Advisory Committee on Immunization Practices ― United States, 2024
MMWR September 12, 2024 / 73(36);799–802
  • PCV (Pneumococcal Conjugate)
  • Pneumococcal
Current
Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR September 12, 2024 / 73(36);793–798
  • COVID-19
Current
Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025
MMWR: Early Release September 10, 2024, 73
  • Influenza
Current
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 Influenza Season
MMWR: August 29, 2024;73(No. RR-5):1–25
  • RSV (Respiratory Syncytial Virus)
Current
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices— United States, 2024
MMWR August 6, 2024
  • COVID-19
Archived
Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR, April 25, 2024 / 73(16);377–381
  • Meningococcal ACWY
  • Meningococcal B
Current
Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices ― United States, 2023
MMWR April 18, 2024 / 73(15);345–350
Current
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024
MMWR, January 11, 2024, 73(1); 11-15
Current
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024
MMWR, January 11, 2024, 73(1); 6-10
  • Polio
Current
Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
MMWR December 8, 2023 / 72(49);1327–1330
  • TBE (Tick-Borne Encephalitis)
Current
Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
MMWR November 10, 2023 / 72(5);1–29
  • COVID-19
Archived
Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
MMWR: October 20, 2023 / 72(42);1140–1146
  • RSV (Respiratory Syncytial Virus)
Current
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
MMWR, October 13, 2023, 72(41);1115-1122
  • PCV (Pneumococcal Conjugate)
  • Pneumococcal
Current
ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children ― United States, 2023
MMWR. 2023 / 72(39);1072
  • COVID-19
Archived
COVID-19 Vaccination Recommendations and Practices for Women of Reproductive Age by Health Care Providers — Fall DocStyles Survey, United States, 2022
MMWR: September 29, 2023 / 72(39);1045–1051
  • PCV (Pneumococcal Conjugate)
  • Pneumococcal
  • PPSV (Pneumococcal Polysaccharide)
Current
Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
MMWR. 2023 / 72(RR-3);1–39
  • RSV (Respiratory Syncytial Virus)
Current
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023
MMWR, August 25, 2023, 72(34); 920–925
  • Influenza
Archived
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season
MMWR; August 25, 2023;72(RR-2);1-25
  • RSV (Respiratory Syncytial Virus)
Current
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices
MMWR, July 21, 2023, 72 (29); 793-801
  • COVID-19
Archived
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
MMWR: June 16, 2023 / 72(24);657–662
Archived
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2023
MMWR, February 10, 2023, 72(6); 137-140
Archived
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2023
MMWR, February 10, 2023, 72(6); 141-144
  • Measles
  • Mumps
  • Rubella
Current
Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices—United States, 2022
MMWR, November 18, 2022, 71 (46); 1465-1470
  • COVID-19
Archived
ACIP Interim Recommendations for the Use of Bivalent Booster Doses of COVID-19 Vaccines—United States, October 2022
MMWR, November 11, 2022, 71(45);1436-1441
  • Cholera
Current
Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022
MMWR, September 30, 2022, 71 (2); 1-8
  • Pneumococcal
Current
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022
MMWR, September 16, 2022, 71(37);1174–1181
  • Influenza
Archived
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022–23 Influenza Season
MMWR, August 26, 2022, 71(1); 1-28
  • COVID-19
Archived
ACIP Interim Recommendation for Use of the Novavax COVID-19 Vaccine in Adults 18 years and older — US, July 2022
MMWR, August 5, 2022, 71(31);988–992
  • COVID-19
Archived
ACIP Interim Recommendations for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
MMWR Early Release June 28, 2022
  • Mpox (Monkeypox)
  • Smallpox
Current
Use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — US, 2022
MMWR, May 27, 2022, Vol 71
  • Rabies
Current
Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices — US, 2022
MMWR, May 6, 2022, 71(18);619–627
  • Hepatitis B
Current
Universal Hepatitis B Vaccination in Adults Aged 19–59 Years, updated ACIP recommendations
MMWR, April 1, 2022, 71(13);477–483
  • COVID-19
Archived
ACIP Recommendation for use of Moderna COVID-19 Vaccine in Adults aged 18 years and older, considerations for extended intervals for primary series doses of mRNA COVID-19 vaccines — US, February 2022
MMWR, March 18, 2022, 71 (11); 416-421
  • Ebola
Current
Use of Ebola Vaccine: Expansion of ACIP Recommendations to include two additional populations, US, 2021
MMWR, February 25, 2022, 71(8);290–292
Archived
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2022
MMWR, February 18, 2022, 71(7); 229-233
Archived
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2022
MMWR, February 18, 2022, 71(7); 234-237
  • Pneumococcal
Current
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR, January 28, 2022, 71 (4); 109-117
  • Zoster (Shingles)
Current
ACIP Recommendations for Use of Recombinant Zoster Vaccine (RZV, Shingrix, GSK) in Immunocompromised Adults aged 19 years and older, US, 2022
MMWR, January 21, 2022, 71(3);80-84
  • COVID-19
Archived
ACIP Updated Interim Recommendations for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine, US, December 2021
MMWR, January 21, 2022, 71(3);90-95
  • COVID-19
Archived
ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years - US, 2021
MMWR Early Release, November 5, 2021, 70
  • COVID-19
Archived
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged 16 Years and older: Recommendations of the Advisory Committee on Immunization Practices — U.S., September 2021
MMWR Early Release, September 21, 2021
  • Influenza
Archived
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2021–22 Influenza Season
MMWR, August 27, 2021, 70(5); 1–28
  • COVID-19
Archived
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from ACIP — US, July 2021
MMWR, August 13, 2021, 70(32);1094-1099
  • COVID-19
Archived
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from ACIP — US, June 2021
MMWR Early Release, July 6, 2021
  • COVID-19
Archived
ACIP Interim Recommendations for use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 years, US, May 2021
MMWR Early Release, May 14, 2021, 70
  • COVID-19
Archived
Updated Recommendation from ACIP for Use of Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — U.S. April 2021
MMWR Early Release, April 27, 2021, 70
  • COVID-19
Archived
ACIP Interim Recommendation for Use of Janssen (Johnson and Johnson) COVID-19 Vaccine - U.S., February 2021
MMWR, March 2, 2021, 70
  • Ebola
Current
Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, U.S., 2020
MMWR, January 8, 2021,70(1);1–12
  • COVID-19
Archived
ACIP Updated Interim Recommendation for Allocation of COVID-19 Vaccine – U.S., December 2020
MMWR, December 22, 2020, 69
  • COVID-19
Archived
ACIP Interim Recommendation for Use of Moderna COVID-19 Vaccine – U.S, December 2020
MMWR, December 20, 2020, 69
  • COVID-19
Archived
ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – U.S., December 2020
MMWR, December 13, 2020, 69
  • COVID-19
Archived
ACIP Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine – U.S., 2020
MMWR, December 3, 2020, 69
  • Meningococcal ACWY
  • Meningococcal B
Current
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices
MMWR, September 25, 2020, Volume 69(9); 1–41
  • Influenza
Archived
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season
MMWR, August 21, 2020, 69 (8); 1–24
  • Hepatitis A
Current
Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices
MMWR, July 3, 2020, Vol 69 (5);1-38
  • Diphtheria
  • Hepatitis B
  • Hib (Haemophilus Influenzae Type B)
  • Pertussis
  • Polio
  • Tetanus
Current
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants
MMWR, February 7, 2020, 69 (5);136-139
  • Diphtheria
  • Pertussis
  • Tetanus
Current
Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR, January 24, 2020, Vol 69 (3);77-83
  • Anthrax
Current
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019
MMWR, December 13, 2019, 68(4);1–14
  • Pneumococcal
Current
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged 65 Years and older: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR, November 22, 2019; 68(46):1069–1075
  • Influenza
Archived
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season
MMWR, August 23, 2019, 68(3); 1–21
  • HPV (Human Papillomavirus)
Current
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR August 16, 2019; 68(32): 698–702

This page was updated on .